[{"orgOrder":0,"company":"SAKK","sponsor":"Oasmia Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"SAKK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAKK \/ SAKK","highestDevelopmentStatusID":"6","companyTruncated":"SAKK \/ SAKK"},{"orgOrder":0,"company":"SAKK","sponsor":"Intensity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Vinblastine Sulfate","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"SAKK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SAKK \/ SAKK","highestDevelopmentStatusID":"8","companyTruncated":"SAKK \/ SAKK"}]

Find Clinical Drug Pipeline Developments & Deals by SAKK

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : The collaboration aims to conduct a phase 2 trial evaluating the clinical and biological effects of intratumoral INT230-6 in early-stage triple-negative breast cancer.

                          Brand Name : INT230-6

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 13, 2024

                          Lead Product(s) : Vinblastine Sulfate,Cisplatin,2-hydroxybenzoyl Amino Octanoate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Intensity Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : SAKK is the legal sponsor of the project and responsible to conduct the phase 1B trial. Oasmia’s main role in the project is to supply its formulation of docetaxel and carry the cost of the trial, which are deemed not material to Oasmia.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 08, 2020

                          Lead Product(s) : Docetaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Oasmia Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank